BriaCell Therapeutics Corp BCTX shares are trading higher Wednesday after the company announced the U.S. Food and Drug Administration granted Fast Track status to Bria-IMT for the treatment of metastatic breast cancer.
Bria-IMT is a cell-based immunotherapy designed to selectively destroy tumor cells without harming the normal cells.
BriaCell is currently enrolling and dosing advanced breast cancer patients in a Phase 1/2a study of Bria-IMT with Incyte's checkpoint inhibitor, retifanlimab, and its immunomodulator, epacadostat in a collaboration with Incyte. The Fast Track designation will apply to patients with metastatic breast cancer. Fast Track improves the speed and frequency of communication with the FDA.
BriaCell is a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer.
See Also: Morning Brief: Top Stories Dominating Financial Media on Wednesday, April 13
BCTX 52-Week Range: $2.81 - $12.47
According to data from Benzinga Pro, the stock was up 12.1% at $11.11 at publication time.
Photo: mohamed_hassan from Pixabay.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
